Abstract
Abstract not available.
Highlights
Sarecycline is a narrow-spectrum tetracycline-class antibiotic designed for the treatment of moderate-tosevere acne
Sarecycline’s narrow-spectrum anti-bacterial activity and lipophilicity may minimize side effects commonly associated with broad-spectrum tetracyclines, such as minocycline and doxycycline
IGA success rates were 21.9% and 22.6% versus 10.5% and 15.3%
Summary
Sarecycline is a narrow-spectrum tetracycline-class antibiotic designed for the treatment of moderate-tosevere acne. Sarecycline’s narrow-spectrum anti-bacterial activity and lipophilicity may minimize side effects commonly associated with broad-spectrum tetracyclines, such as minocycline and doxycycline. We report the results of 2 identically designed, phase 3 pivotal trials, SC1401 and SC1402, to evaluate the efficacy and safety of once-daily sarecycline (n=2002)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
